483 related articles for article (PubMed ID: 16504675)
1. Conversion to sirolimus from cyclosporine may induce nephrotic proteinuria and progressive deterioration of renal function in chronic allograft nephropathy patients.
Boratyńska M; Banasik M; Watorek E; Falkiewicz K; Patrzałek D; Szyber P; Klinger M
Transplant Proc; 2006; 38(1):101-4. PubMed ID: 16504675
[TBL] [Abstract][Full Text] [Related]
2. Conversion to sirolimus for chronic allograft nephropathy and calcineurin inhibitor toxicity and the adverse effects of sirolimus after conversion.
Sayin B; Karakayali H; Colak T; Sevmis S; Pehlivan S; Demirhan B; Haberal M
Transplant Proc; 2009 Sep; 41(7):2789-93. PubMed ID: 19765436
[TBL] [Abstract][Full Text] [Related]
3. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
Bumbea V; Kamar N; Ribes D; Esposito L; Modesto A; Guitard J; Nasou G; Durand D; Rostaing L
Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508
[TBL] [Abstract][Full Text] [Related]
4. Proteinuria after conversion to sirolimus in renal transplant recipients.
Sahin GM; Sahin S; Kantarci G; Ergin H
Transplant Proc; 2006 Dec; 38(10):3473-5. PubMed ID: 17175308
[TBL] [Abstract][Full Text] [Related]
5. Increase of proteinuria after conversion from calcineurin inhibitor to sirolimus-based treatment in kidney transplant patients with chronic allograft dysfunction.
Ruiz JC; Campistol JM; Sánchez-Fructuoso A; Rivera C; Oliver J; Ramos D; Campos B; Arias M; Diekmann F
Nephrol Dial Transplant; 2006 Nov; 21(11):3252-7. PubMed ID: 16954170
[TBL] [Abstract][Full Text] [Related]
6. Conversion from calcineurin inhibitor to sirolimus in pediatric chronic allograft nephropathy.
Falger JC; Mueller T; Arbeiter K; Boehm M; Regele H; Balzar E; Aufricht C
Pediatr Transplant; 2006 Jun; 10(4):474-8. PubMed ID: 16712606
[TBL] [Abstract][Full Text] [Related]
7. Clinical implications of proteinuria in renal transplant recipients switching to rapamycin for chronic allograft dysfunction.
Gutiérrez MJ; González E; Andrés A; Morales JM
Transplant Proc; 2009; 41(6):2348-50. PubMed ID: 19715916
[TBL] [Abstract][Full Text] [Related]
8. Conversion to sirolimus allows preservation of renal function in kidney and kidney-pancreas allograft recipients.
Laham G; Sleiman S; Soler Pujol G; Diaz C; Dávalos M; Vilches A
Transplant Proc; 2010; 42(1):309-13. PubMed ID: 20172338
[TBL] [Abstract][Full Text] [Related]
9. The effect of sirolimus in the development of chronic allograft nephropathy.
Gürkan A; Kaçar S; Erdoğdu U; Varilsüha C; Kandemir G; Karaca C; Akman F
Transplant Proc; 2008; 40(1):114-6. PubMed ID: 18261561
[TBL] [Abstract][Full Text] [Related]
10. Sirolimus delays recovery from posttransplant renal failure in kidney graft recipients.
Boratyńska M; Banasik M; Patrzalek D; Szyber P; Klinger M
Transplant Proc; 2005 Mar; 37(2):839-42. PubMed ID: 15848550
[TBL] [Abstract][Full Text] [Related]
11. Sirolimus in chronic allograft nephropathy in pediatric recipients.
Ibáñez JP; Monteverde ML; Diaz MA; Goldberg J; Turconi AF
Pediatr Transplant; 2007 Nov; 11(7):777-80. PubMed ID: 17910656
[TBL] [Abstract][Full Text] [Related]
12. Complete switch to everolimus in long-term kidney transplants: evolution of the renal function.
Fernández A; Marcén R; Galeano C; Caldés S; Amezquita Y; Villafruela J; Pascual J; Burgos J; Rodríguez-Mendiola N; Ortuño J
Transplant Proc; 2009; 41(6):2345-7. PubMed ID: 19715915
[TBL] [Abstract][Full Text] [Related]
13. Is sirolimus a safe alternative to reduce or eliminate calcineurin inhibitors in chronic allograft nephropathy in kidney transplantation?
Lai WJ; Chiang YJ; Chen Y; Chu SH
Transplant Proc; 2004 Sep; 36(7):2056-7. PubMed ID: 15518744
[TBL] [Abstract][Full Text] [Related]
14. Tubular toxicity in sirolimus- and cyclosporine-based transplant immunosuppression strategies: an ancillary study from a randomized controlled trial.
Franz S; Regeniter A; Hopfer H; Mihatsch M; Dickenmann M
Am J Kidney Dis; 2010 Feb; 55(2):335-43. PubMed ID: 19926370
[TBL] [Abstract][Full Text] [Related]
15. Sirolimus conversion experience in a single center.
Wang HH; Huang JY; Chu SH; Chiang YJ; Liu KL; Lai PC
Transplant Proc; 2008 Sep; 40(7):2209-10. PubMed ID: 18790194
[TBL] [Abstract][Full Text] [Related]
16. Immunosuppression modifications and graft outcome in patients with chronic allograft nephropathy.
El-Agroudy AE; El-Dahshan K; Mahmoud K; Ismail AM; El-Baz M; Shokeir AA; Ghoneim MA
Exp Clin Transplant; 2008 Sep; 6(3):203-10. PubMed ID: 18954298
[TBL] [Abstract][Full Text] [Related]
17. Late conversion from calcineurin inhibitor-based to sirolimus-based immunosuppression due to chronic toxicity: a prospective study with protocol biopsy amendment.
Uslu A; Töz H; Sen S; Alkan FT; Nart A; Aykas A; Doğan M; Postaci H; Sahin T; Simşek C
Transplant Proc; 2009 Mar; 41(2):756-63. PubMed ID: 19328973
[TBL] [Abstract][Full Text] [Related]
18. Conversion from calcineurin inhibitor to sirolimus in pediatric chronic allograft nephropathy.
Falger JC; Mueller T; Arbeiter K; Boehm M; Regele H; Balzar E; Aufricht C
Pediatr Transplant; 2006 Aug; 10(5):565-9. PubMed ID: 16856992
[TBL] [Abstract][Full Text] [Related]
19. Minimization of maintenance immunosuppression early after renal transplantation: an interim analysis.
Bemelman FJ; de Maar EF; Press RR; van Kan HJ; ten Berge IJ; Homan van der Heide JJ; de Fijter HW
Transplantation; 2009 Aug; 88(3):421-8. PubMed ID: 19667948
[TBL] [Abstract][Full Text] [Related]
20. The combination of sirolimus and cyclosporine does not delay initial renal graft function recovery.
Hsu HJ; Tian YC; Chen YC; Lai BC; Fang JT; Yang CW; Wu MS
Ren Fail; 2008; 30(3):303-6. PubMed ID: 18350450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
